No Vaccine, No Cure

Editor's Note: This is the second of two articles that looks at the progression of AIDS research over the 20 years since its identification. The first part: M.E. Watanabe, "AIDS, 20 years later," The Scientist, 15[12]:1, June 11, 2001. Despite billions of dollars spent in research funds and a brief reprieve in Western nations after the introduction of multidrug therapy, AIDS continues to win its battle against humankind. First diagnosed 20 years ago, there are still no cures and no vaccines. Pre

| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

When first diagnosed in the United States, the disease mainly struck gay men, intravenous drug abusers, and those who had received tainted blood or blood products. Today, its targets have changed. AIDS thrives in poverty and among those who are disenfranchised. Increasingly, it is becoming a disease affecting women and children: worldwide, in 2000, 2.2 million of the 4.7 million new HIV infections were in women.1

In the United States, "it continues to disproportionately [strike] communities of color," says Helene Gayle, the outgoing director of the Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention. "Almost 70 percent of new HIV infections are among African Americans and Latinos." Moreover, the prevalence of AIDS in gay men in the United States is no longer declining, after years of decreasing. "It's not enough to tell people that this is AIDS and how you get it," says Karungari ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Myrna Watanabe

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo